Smoking cessation in patients with psychiatric disorders

Journal of Clinical Psychiatry

Volumn 68, Issue 9, 2007, Pages 1404-1410

  Gelenberg, Alan J ^a   De Leon, Jose ^b   Evins, A Eden ^c   Parks, Joseph J ^d   Rigotti, Nancy A ^e  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b Eastern State Hospital   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d State of Missouri ^*  (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; CLONIDINE; CLOZAPINE; NEUROLEPTIC AGENT; NICOTINIC AGENT; NORTRIPTYLINE; OLANZAPINE; SEROTONIN UPTAKE INHIBITOR; VARENICLINE;

ALCOHOLISM; CIGARETTE SMOKING; COGNITIVE BEHAVIORAL STRESS MANAGEMENT; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG METABOLISM; HUMAN; MENTAL DISEASE; NICOTINE REPLACEMENT THERAPY; NOTE; PRIORITY JOURNAL; PSYCHOEDUCATION; PSYCHOSOCIAL CARE; RELAPSE; SCHIZOPHRENIA; SELF MEDICATION; SMOKING CESSATION; SOCIAL PSYCHOLOGY; TOBACCO DEPENDENCE; UNSPECIFIED SIDE EFFECT;

EID: 34948902886     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v68n0912     Document Type: Note

References (76)

1. Center for Disease Control and Prevention (CDC). Cigarette smoking among adults: United States, 2004. MMWR Morb Mortal Wkly Rep 2005;54:1121-1124
2. Mokdad AH, Marks JS, Stroup DF, et al. Actual causes of death in the United States, 2000. JAMA 2004;291:1238-1319
3. Lasser K, Boyd JW, Woolhandler S, et al. Smoking and mental illness: a population-based prevalence study. JAMA 2000;284:2606-2610
4. Haustein KO, Haffner S, Woodcock BG. A review of the pharmacological and psychopharmacological aspects of smoking and smoking cessation in psychiatric patients. Int J Clin Pharmacol 2002;40:404-418
5. Vokes NI, Bailey JM, Rhodes KV. "Should I give you my smoking lecture now or later?": characterizing emergency physician smoking cessation and cessation counseling. Ann Emerg Med 2006;48:406-414
6. Law M, Tang JL. An analysis of the effectiveness of interventions intended to help people stop smoking. Arch Intern Med 1995;155:1933-1941
7. Wilson DM, Lindsay EA, Best JA, et al. A smoking cessation intervention program for family physicians. CMAJ 1987;137:613-619
8. de Leon J, Susce MT, Diaz FJ, et al. Variables associated with alcohol, drug, and daily smoking cessation in patients with severe mental illnesses. J Clin Psychiatry 2005;66:1447-1455
9. Diaz FJ, Jane M, Salto E, et al. A brief measure of high nicotine dependence for busy clinicians and large epidemiological surveys. Aust N Z J Psychiatry 2005;39:161-168
10. Heatherton TF, Kozlowski LT, Frecker RC, et al. The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire. Br J Addict 1991;86:1119-1127
11. Fagerstrom KO, Schneider NG. Measuring nicotine dependence: a review of the Fagerstrom Tolerance Questionnaire. J Behav Med 1989;12:159-182
12. Robinson MD, Laurent SL, Little JM Jr. Including smoking status as a new vital sign: it works! J Fam Pract 1995;40:556-561
13. Evins AE, Cather C, Rigotti NA, et al. Two-year follow-up of a smoking cessation trial in patients with schizophrenia: increased rates of smoking cessation and reduction. J Clin Psychiatry 2004;65:307-311
14. Olincy A, Young DA, Freedman R. Increased levels of the nicotine metabolite cotinine in schizophrenic smokers compared to other smokers. Biol Psychiatry 1997;42:1-5
15. Tidey JW, Rohsenow DJ, Kaplan GB, et al. Cigarette smoking topography in smokers with schizophrenia and matched non-psychiatric controls. Drug Alcohol Depend 2005;80:259-265
16. de Leon J, Armstrong SC, Cozza KL. The dosing of atypical antipsychotics. Psychosomatics 2005;46:262-273
17. de Leon J. Atypical antipsychotic dosing: the effect of smoking and caffeine. Psychiatr Serv 2004;55:491-493
18. Rostami-Hodjegan A, Amin AM, Spencer EP, et al. Influence of dose, cigarette smoking, age, sex, and metabolic activity on plasma clozapine concentrations: a predictive model and nomograms to aid clozapine dose adjustment and to assess compliance in individual patients. J Clin Psychopharmacol 2004;24:70-78
19. van der Weide J, Steijns LS, van Weelden MJ. The effect of smoking and cytochrome P450 CYP1A2 genetic polymorphism on clozapine clearance and dose requirement. Pharmacogenetics 2003;13:169-172
20. Salokangas RK, Saarijarvi S, Taiminen T, et al. Effect of smoking on neuroleptics in schizophrenia. Schizophr Res 1997;23:55-60
21. Seppala NH, Leinonen EV, Lehtonen ML, et al. Clozapine serum concentrations are lower in smoking than in non-smoking schizophrenic patients. Pharmacol Toxicol 1999;85:244-246
22. Desai HD, Seabolt J, Jann MW. Smoking in patients receiving psychotropic medications: a pharmacokinetic perspective. CNS Drugs 2001;15:469-494
23. Theisen FM, Haberhausen M, Schultz E, et al. Serum levels of olanzapine and its N-desmethyl and 2-hydroxymethyl metabolites in child and adolescent psychiatric disorders: effects of dose, diagnosis, age, sex, smoking, and comedication. Ther Drug Monit 2006;28:750-759
24. Mastropaolo J, Rosse RB, Deutsch SI. Anabasine, a selective nicotinic-acetylcholine receptor agonist, antagonizes MK-801-elicited mouse popping behavior, an animal model of schizophrenia. Behav Brain Res 2004;153:419-422
25. Paterson D, Nordberg A. Neuronal nicotinic receptors in the human brain. Prog Neurobiol 2000;61:75-111
26. Hogg RC, Raggenbass M, Bertrand D. Nicotinic acetylcholine receptors: from structure to brain function. Rev Physiol Biochem Pharmacol 2003;147:1-46
27. Court JA, Martin-Ruiz C, Graham A, et al. Nicotinic receptors in human brain: topography and pathology. J Chem Neuroanat 2000;20:281-298
28. Ripoll N, Bronnec M, Bourin M. Nicotinic receptors and schizophrenia. Curr Med Res Opin 2004;20:1057-1074
29. Leonard S, Adams C, Breese CR, et al. Nicotinic receptor function in schizophrenia. Schizophr Bull 1996;22:431-445
30. Leonard S, Gault J, Hopkins J, et al. Association of promoter variants in the alpha7 nicotinic acetylcholine receptor subunit gene with an inhibitory deficit found in schizophrenia. Arch Gen Psychiatry 2002;59:1085-1096
31. Freedman R, Hall M, Adler LE, et al. Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia. Biol Psychiatry 1995;38:22-33
32. Durany N, Zochling R, Boissl KW, et al. Human post-mortem striatal alpha4beta2 nicotinic acetylcholine receptor density in schizophrenia and Parkinson's syndrome. Neurosci Lett 2000;287:109-112
33. Breese CR, Lee MJ, Adams CE, et al. Abnormal regulation of high affinity nicotinic receptors in subjects with schizophrenia. Neuropsychopharmacology 2000;23:351-364
34. Adler LE, Hoffer LD, Wiser A, et al. Normalization of auditory physiology by cigarette smoking in schizophrenic patients. Am J Psychiatry 1993;150:1856-1861
35. Adler LE, Hoffer LJ, Griffith J, et al. Normalization by nicotine of deficient auditory sensory gating in the relatives of schizophrenics. Biol Psychiatry 1992;32:607-616
36. Tanabe J, Tregellas JR, Martin L.F. Effects of nicotine on hippocampal and cingulate activity during smooth pursuit eye movement in schizophrenia. Biol Psychiatry 2006;59:754-761
37. Tregellas JR, Tanabe JL, Martin LF, et al. FMRI of response to nicotine during a smooth pursuit eye movement task in schizophrenia. Am J Psychiatry 2005;162:391-393
38. Avila MT, Sherr JD, Hong E, et al. Effects of nicotine on leading saccades during smooth pursuit eye movements in smokers and nonsmokers with schizophrenia. Neuropsychopharmacology 2003;28:2184-2191
39. Olincy A, Johnson LL, Ross RG. Differential effects of cigarette smoking on performance of a smooth pursuit and a saccadic eye movement task in schizophrenia. Psychiatry Res 2003;117:223-236
40. Barr RS, Culhane MA, Jubelt LE, et al. The effects of transdermal nicotine on cognition in nonsmokers with schizophrenia and nonpsychiatric controls. Neuropsychopharmacology 2007;[Epub ahead of print]
41. de Leon J, Diaz FJ, Aguilar MC, et al. Does smoking reduce akathisia? testing a narrow version of the self-medication hypothesis. Schizophr Res 2006;86:256-268
42. de Leon J. Smoking and vulnerability for schizophrenia. Schizophr Bull 1996;22:405-409
43. de Leon J, Diaz FJ. A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors. Schizophr Res 2005;76:135-157
44. Osler M, Holst C, Prescott E, et al. Influence of genes and family environment on adult smoking behavior assessed in an adoption study. Genet Epidemiol 2001;21:193-200
45. Kendler KS, Thornton LM, Pedersen NL. Tobacco consumption in Swedish twins reared apart and reared together. Arch Gen Psychiatry 2000;57:886-892
46. Straub RE, Sullivan PF, Ma Y, et al. Susceptibility genes for nicotine dependence: a genome scan and follow up in an independent sample suggest that regions on chromosomes 2, 4, 10, 16, 17, and 18 merit further study. Mol Psychiatry 1999;4:129-144
47. Lerman C, Caporaso NE, Audrain J, et al. Interacting effects of the serotonin transporter gene and neuroticism in smoking practices and nicotine dependence. Mol Psychiatry 2000;5:189-192
48. Lerman C, Berrettini W. Elucidating the role of genetic factors in smoking behavior and nicotine dependence. Am J Med Genet B Neuropsychiatr Genet 2003;118:48-54
49. Beuten J, Payne TJ, Ma JZ, et al. Significant association of catechol-O-methyltransferase (COMT) haplotypes with nicotine dependence in male and female smokers of 2 ethnic populations. Neuropsychopharmacology 2006;31:675-684
50. Berrettini WH, Wileyto EP, Epstein L, et al. Catechol-O-methyltransferase (COMT) gene variants predict response to bupropion therapy for tobacco dependence. Biol Psychiatry 2007;61:111-118
51. Lerman C, Jepson C, Wileyto EP, et al. Role of functional genetic variation in the dopamine D2 receptor (DRD2) in response to bupropion and nicotine replacement therapy for tobacco dependence: results of 2 randomized clinical trials. Neuropsychopharmacology 2006;31:231-242
52. Johnstone EC, Yudkin PL, Hey K, et al. Genetic variation in dopaminergic pathways and short-term effectiveness of the nicotine patch. Pharmacogenetics 2004;14:83-90
53. Diaz FJ. Epidemiology of comorbid tobacco use and schizophrenia: thinking about risks and protective factors. J Dual Diagnosis. In press.
54. Tyndale RF, Sellers EM. Genetic variation in CYP2A6-mediated nicotine metabolism alters smoking behavior. Ther Drug Monit 2002;24:163-171
55. Colton CW, Manderscheid RW. Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. Prev Chonic Dis [Serial Online] 2006;3:1-14
56. US Public Health Service. A Clinical Practice Guideline for Treating Tobacco Use and Dependence: a US Public Health Service report. The Tobacco Use and Dependence Clinical Practice Guideline Panel, Staff, and Consortium Representatives. JAMA 2000;283:3244-3254
57. Evins AE, Mays VK, Rigotti NA, et al. A pilot trial of bupropion added to cognitive behavioral therapy for smoking cessation in schizophrenia. Nicotine Tob Res 2001;3:397-403
58. Weiner E, Ball MP, Summerfelt A, et al. Effects of sustained-release bupropion and supportive group therapy on cigarette consumption in patients with schizophrenia. Am J Psychiatry 2001;158:635-637
59. George TP, Vessicchio JC, Termine A, et al. A placebo controlled trial of bupropion for smoking cessation in schizophrenia. Biol Psychiatry 2002;52:53-61
60. Evins AE, Cather C, Deckersbach T, et al. A double-blind placebo-controlled trial of bupropion sustained-release for smoking cessation in schizophrenia. J Clin Psychopharmacol 2005;25: 218-225
61. Evins AE, Cather C, Culhane MA, et al. A double-blind placebo-controlled study of bupropion SR added to high-dose, dual nicotine replacement therapy for smoking cessation or reduction in schizophrenia. J Clin Psychopharmacol. In press
62. Cui Y, Wen W, Moriarty CJ, et al. Risk factors and their effects on the dynamic process of smoking relapse among veteran smokers. Behav Res Ther 2006;44:967-981
63. Williams JM, Foulds J. Successful tobacco dependence treatment in schizophrenia. Am J Psychiatry 2007;164:222-227
64. Baker A, Richmond R, Haile M, et al. A randomized controlled trial of a smoking cessation intervention among people with a psychotic disorder. Am J Psychiatry 2006;163:1934-1942
65. Breslau N, Kilbey M, Andreski P. Nicotine dependence, major depression, and anxiety in young adults. Arch Gen Psychiatry 1991;48:1069-1074
66. Breslau N, Kilbey MM, Andreski P. Nicotine dependence and major depression: new evidence from a prospective investigation. Arch Gen Psychiatry 1993;50:31-35
67. Glassman AH, Helzer JE, Covey LS, et al. Smoking, smoking cessation, and major depression. JAMA 1990;264:1546-1549
68. Hughes JR, Hatsukami DK, Mitchell JE, et al. Prevalence of smoking among psychiatric outpatients. Am J Psychiatry 1986;143:993-997
69. Tsoh JY, Humfleet GL, Munoz RF, et al. Development of major depression after treatment for smoking cessation. Am J Psychiatry 2000;157:368-374
70. Hughes JR, Stead L, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev 2007:CD000031
71. Wilhelm K, Arnold K, Niven H, et al. Grey lungs and blue moods: smoking cessation in the context of lifetime depression history. Aust N Z J Psychiatry 2004;38:896-905
72. Taylor NE, Rosenthal RN, Chabus B, et al. The feasibility of smoking bans on psychiatric units. Gen Hosp Psychiatry 1993;15 :36-40
73. Beemer BR. Hospital psychiatric units: nonsmoking policies. J Psychosoc Nurs Mem Health Serv 1993;31:12-14
74. Haller E, McNiel DE, Binder RL. Impact of a smoking ban on a locked psychiatric unit. J Clin Psychiatry 1996;57:329-332
75. Velasco J, Eells TD, Anderson R, et al. A two-year follow-up on the effects of a smoking ban in an inpatient psychiatric service. Psychiatr Serv 1996;47:869-871
76. Greeman M, McClellan TA. Negative effects of a smoking ban on an inpatient psychiatry service. Hosp Community Psychiatry 1991;42:408-412